Kornimate/medical-research-clean huggingface dataset:
assessment of tear production, corneal staining, and comfort level wearing different types of contact lenses

Conditions: Dry Eye; Dry Eye Syndromes; Contact Lens-induced Corneal Fluorescein Staining

Summary: this research assesses the tear performance of five distinct types of soft contact lenses commonly found in the market. the study involves contact lens participants, all of whom are students enrolled at ukm. before the study, participants were instructed to discontinue wearing their usual contact lenses for two weeks. the lenses utilized in this clinical trial all possess current refractive power. participants are required to wear the lenses for an entire day only. upon completion of the study, participants will be requested to complete a brief questionnaire.

before commencing the trial, all participants will undergo an anterior segment examination to ensure the eyes are in a healthy state, free from corneal diseases. two parameters will be measured during this examination: tear break-up time (tbut), which is a non-invasive method used to assess tear break-up, and the schirmer test, where a strip is placed on the lower eyelid for five minutes to evaluate tear wetting of the strip. the level of comfort after wearing contact lenses for 8 hours will be assessed using the contact lens discomfort index questionnaire. the sample size is determined using the formula by daniel (1999). ten percent of the total sample size represents the number of subjects for this study. considering a dropout rate of 10%, this study requires 18 subjects.

Eligibility criteria:
inclusion criteria: * healthy volunteers * age 19-29 years old * refractive error is less than -6.00ds with astigmatism is less than -1.00dc * have experience wearing contact lenses but agree to stop wearing them for 2 weeks before the study starts exclusion criteria: * smokers (ward et al. 2010) * participants with ocular disease or trauma which includes lasik patients and intra/extraocular surgery. * pregnant females (yenerel \& kucumen 2015). * participants taking medication for systemic diseases (fraunfelder et al. 2012).

Keywords: dry eye contact lens corneal staining tears comfort
efficacy of anti-tubercular vaccination in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the frequency of auto-immune diseases (including multiple sclerosis) is increasing in industrialised countries. according to an hypothesis which is receiving a wide international credit, this may be due to the fact that the populations of these countries are increasingly less exposed to microbes further to the improvement of hygienic conditions and to the use of antibiotics. if exposure to microbes is lacking, also their regulatory function is missed with a consequent possible onset of auto-immune symptoms. for this reason, it is deemed that by exposing the immune system of a patient to an ancient microbe, being complex and important in man evolution, like the tuberculosis mycobacterium, it is possible to rebalance the immune system.

vaccination with the tuberculosis mycobacterium has proved to be effective in the animal model of multiple sclerosis, experimental allergic encephalitis. in a study of phase i-ii our group has demonstrated the safety of this therapy together with preliminary evidence. the study includes patients with an initial disease (diagnosis supported by paraclinical criteria): single clinical poly or mono-symptomatic attack in the 6 months preceding the study, mr picture compatible with ms. study design 100 randomized patients (i.e. randomly assigned) to be included either in a group of 50 patients undergoing therapy or to a group of 50 patients receiving placebo. patients are followed up with monthly contrast mri for 6 months. at the end of the six months the disease activity in the group of treated patients is benchmarked with the disease activity of the group of patients receiving placebo. safety is granted by the extremely wide diffusion of this kind of vaccination worldwide and by the previous study in patients affected by multiple sclerosis.

Eligibility criteria:
inclusion criteria: * patients with an initial disease (diagnosis supported by paraclinical criteria): single clinical poly or mono-symptomatic attack in the 6 months preceding the study, mr picture compatible with ms exclusion criteria: * therapy with corticosteroids in the last month * plasmapheresis, administration of gamma globulins in the last three months * serious heart, renal, hepatic or haematological dysfunction defined by laboratory exams * evidence of infections * evidence of tubercular disease

Keywords: multiple sclerosis tuberculosis vaccine therapy
ct in diagnosing patients with lung cancer

Conditions: Lung Cancer

Summary: this clinical trial studies computed tomography (ct) in diagnosing patients with lung cancer. diagnostic procedures, such as ct, may help find and diagnose lung cancer.

primary objectives: i. conduct a prospective clinical imaging study to quantify the amount of inter- and intra-physician contouring variability on four dimensional (4d) ct, active breathing control (abc) ct, free breathing ct, and free breathing and abc cone beam (cb)ct. ii. quantify the magnitude and distribution of target and organ at risk volume variations between the different imaging modalities. iii. determine dosimetric changes related to contouring variations for tumor and normal tissue. outline: patients undergo conventional free breathing ct, 4d ct, abc ct, abc cbct, and free breathing cbct before undergoing radiation therapy.

Eligibility criteria:
inclusion criteria: * measurable disease on ct scan * patients with lung cancer visible on ct who are scheduled to receive external beam radiation treatment will be eligible for this study * patients must be able to perform abc procedures exclusion criteria: * patients requiring continuous supplemental oxygen due to the requirement of spirometry during all imaging studies * no vulnerable populations will be enrolled (prisoners, children, pregnant females or institutionalized individuals) * women of childbearing potential will undergo a pregnancy test
study of anti-cd19 car nk cells in relapsed and refractory b cell lymphoma

Conditions: Refractory B-Cell Lymphoma

Summary: this is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti cd19 car nk cells in patients with relapsed refractory b cell lymphoma.


Eligibility criteria:
inclusion criteria: 1. cd19 (+) b cell lymphoma confirmed by pathological immunohistochemistry or flow cytometry 2. previously accepted ≥ first-line regimen chemotherapy 3. unconditional acceptance of hematopoietic stem cell transplantation or recurrence after hematopoietic stem cell transplantation 4. over 18 years old and under 70 years old 5. the expected survival period is more than 3 months. 6. ecog≤2 7. important organ function is satisfied: cardiac ultrasound indicates cardiac ejection fraction ≥50%, no abnormal electrocardiogram; blood oxygen saturation ≥90%; creatinine clearance ≥40 ml/min; alt and ast≤3 times normal range, total bilirubin ≤ 2.0 mg / dl; 8. blood routine: hgb≥80 g/l, anc≥1×109/l, plt≥50×109/l; 9. the pregnancy test for women of childbearing age must be negative; both men and women must agree to use effective contraception during the treatment period and for the following 1 year. 10. measurable target lesion exclusion criteria: 1. patients with extramedullary relapse 2. burkitt's lymphoma/leukemia 3. previously received gene product treatment, anti-cd19/anti-cd3 treatment, or any anti-cd19 treatment; 4. liver and kidney function: * total bilirubin \> 2 x uln (gilbert syndrome \> 3 x uln) * aspartate aminotransferase (ast) and alanine aminotransferase (alt) \> 3 × uln * serum creatinine clearance \>60 ml/min 5. serological examination: * absolute neutrophil count (anc) \<0.75x109/l * platelet count (plt) \<50x109/l 6. active hepatitis b (hbv-dna \> 1000 copies / ml), hepatitis c, or uncontrolled infection 7. gvhd ≥ 2 or anti-gvhd treatment 8. im19 car nk cells received allogeneic cell therapy within 6 weeks before infusion, such as donor lymphocyte infusion; 9. subject received the most recent treatment (release, chemotherapy, or other) less than 4 weeks 10. active cns disease (tumor cells in csf, but \< 5 wbcs/ml can be included); 11. intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular internal coagulation 12. creatinine \> 1.5 times normal upper limit or alt / ast \> 3 times normal upper limit or bilirubin \> 2 times normal upper limit 13. new york heart association (nyha) graded above or above 14. uncontrollable diabetes 15. suffering from other uncontrolled diseases, the researchers believe that it is not suitable for joining 16. any situation that the investigator believes may increase the risk of the subject or interfere with the test results
chitinases and transforming growth factor beta (tgfb) in human asthma

Conditions: Asthma

Summary: the purpose of this study is to find out the roles of two specific gene families (the chitinase gene family and the tgfb family). we hypothesize that chitinases and tgfb pathway genes will be differentially expressed in the airways of non-asthmatic subjects and subjects with asthma. we further hypothesize that genetic variants in chit1, amcase, and tgfb pathway genes that show associations with asthma and related phenotypes will change the expression and/or function of the protein of these genes in the airway in several ways, including the transcript numbers for full length genes and splice variants and, for the chitinase genes, the levels of chitinase activity in airway secretions.

this is a cross-sectional study in patients with asthma and healthy controls in which we will analyze how the expression or function of chit1, amcase, and tgfb pathway genes in the asthmatic airway is affected by genetic variation in these genes. we propose detailed phenotyping of the asthmatic subjects and the healthy controls, including collection of induced sputum, exhaled air and detailed physiologic measures including measures of airflow, lung volumes, and methacholine responsiveness as well as collection of airway cells and tissues by bronchoscopy. we will determine the relative expression of chit1 and amcase in specific lung compartments (large airways, small airways, epithelial cells, macrophages) and the effects of genetic variants in chit1 and amcase on expression of splice variants and levels of chitinase activity in the airway. these human samples will also allow us to determine if any of the multiple tgfb pathway genes analyzed show differential expression in the lung in asthma.

Eligibility criteria:
inclusion criteria: * history of asthma * no use of oral or inhaled corticosteroids for the treatment of asthma in the past 6 weeks * hyperreactivity to methacholine (pc20fev1 methacholine ≤ 8.0 mg/ml). * at least one of the following symptoms, beta agonist use, or fev1 criteria: * asthma symptoms on at least two days per week, or * beta agonist use on at least two days per week, or * fev1 \< 85% predicted * subjects must be non-smokers (patients who have never smoked or patients who have not smoked for 1 year and have a total pack-year smoking history \< 10 packs). exclusion criteria: * cigarette smoking: subjects must be non-smokers. non smokers are defined as subjects who have never smoked or who have not smoked for 1 year and have a total pack-year smoking history \< 10 packs. * pregnant women * subjects with a history of a medical disease which in the opinion of the investigator may put the subject at extra risk from study-related procedures or because the disease may influence the results of the study. * healthy control subjects must have no history of asthma or allergic rhinitis * upper respiratory tract infection in the 4 weeks prior to enrollment in the study
phase 1 study of e7090 in subjects with solid tumor

Conditions: Tumors

Summary: this is a phase 1 study of e7090 in subjects with advanced solid tumors. this study will be conducted in 2 parts: 1. part 1 will be the dose escalation portion of this study to determine the maximum tolerated dose in subjects with solid tumors, and 2. part 2 will comprise cohort expansions to further characterize the safety and tolerability of e7090 and to assess preliminary efficacy of e7090 in subjects with solid tumors characterized by genetic abnormalities in fgf/fgfr pathway.


Eligibility criteria:
inclusion criteria: part 1and part 2 1. provide written informed consent 2. male or female subjects age \>= 20 years at the time of informed consent 3. subjects with a histological and/or cytological diagnosis of solid tumor 4. subjects who failed standard therapies, or for which no appropriate treatment is available. 5. subjects with performance status (ps) score of 0-1 established by eastern cooperative oncology group (ecog) 6. subjects who are expected to survive for 3 months or longer after starting administration of the investigational drug. inclusion criteria: part 2 only 7. subjects with tumor expressing genetic abnormality in fgf/fgfr (fibroblast growth factor/ fibroblast growth factor receptor)pathway. exclusion criteria 1. patients with brain metastasis who have clinical symptoms or requiring treatment. 2. medical history of clinically significant cardiovascular impairment 3. concomitant systemic infection requiring medical treatment 4. effusion requiring drainage 5. known intolerance to the study drug (or any of excipients) 6. subjects whose toxicity of previous treatment has not recovered to grade 1 or lower (except for alopecia). 7. inability to take oral medication, or malabsorption syndrome, or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of e7090. 8. psychiatric disorder (e.g., alcohol or drug dependency) judged to be ineligible for study entry by the investigator or subinvestigator 9. females who are pregnant or breastfeeding 10. any subjects who are judged by the principal investigator or the other investigators to be inappropriate as subjects in this clinical study.

Keywords: solid tumors e7090
evaluation of molecular hydrogen supplementation to enhance the efficacy of weight loss retreat in overweight and obese adolescents

Conditions: Body Composition; Fitness; Insulin Sensitivity; Lipid Profile; Oxidative Stress; Inflammation; Autonomic Nervous System Activity

Summary: this randomized controlled trial evaluates whether molecular hydrogen supplementation enhances the effectiveness of a 4-week weight loss retreat in overweight and obese adolescents. outcome measures include: body composition, physical status, blood samples (insulin sensitivity, lipid profiles, markers of oxidative stress and inflammation) and autonomic nervous system function.

the aim of this randomized, double-blind, parallel-group, placebo-controlled trial is to evaluate whether molecular hydrogen supplementation enhances the effectiveness of weight loss retreat for overweight and obese adolescents. weight loss retreat is indicated for participants based on diagnosis and recommendation of a pediatrician. during the 4-week retreat, participants follow a prescribed standardized intervention consisting of reduction diet and physical activity. the total planned number of participants is 60. participants are randomly divided into two balanced groups, with one group receiving molecular hydrogen in the form of hydrogen-rich water and the other receiving a placebo water. the daily amount of water given (hydrogen-rich or placebo) is 1.5 l. hydrogen-rich water is packaged in specially designed aluminum containers to minimize hydrogen leakage and ensure long-term stability with a dissolved hydrogen concentration of 1.2-1.6 ppm. participants are unable to distinguish hydrogen-rich water from the placebo because molecular hydrogen is colorless, odorless, and tasteless. participants monitor their physical activity, sleep, and sedentary behavior one week before to retreat and undergo baseline diagnostics (including blood sampling), three weekly interim diagnostics during retreat, and final diagnostics (including blood sampling) after four weeks. if participants are available, two follow-up diagnostics are conducted six weeks and six months after the retreat and include seven-day monitoring of physical activity, sleep, and sedentary behavior. statistical analysis is performed at a significance level of α = 0.05 and the data is evaluated using analysis of variance. in cases of non-normality, data transformations or non-parametric alternatives are used.

Eligibility criteria:
inclusion criteria: * body mass index indicating overweight or obesity, as determined according to the world health organization's international percentile charts for children aged 5-19 years. * presence of a regular menstrual cycle in female participants. * signed informed consent from the legal representative. exclusion criteria: * high blood pressure. * dyslipoproteinemia. * cardio-respiratory disorders. * musculoskeletal disorders. * use of any medications regulating heart rhythm or the neurovegetative and hormonal system.
meditation-relaxation (mr therapy) for sleep paralysis.

Conditions: Sleep Paralysis; Narcolepsy Type 1

Summary: the aim of the study is to evaluate, with a small-scale pilot study, the efficacy of meditation relaxation therapy for sleep paralyses in patients with narcolepsy. the study involves two arms, with intervention with meditation relaxation therapy or sham over a period of three months.


Eligibility criteria:
inclusion criteria: * narcolepsy (type 1 and 2) based on polysomnography, multiple sleep latency test \[mlst\] and csf hypocretin level testing). * patients had to have experienced sp at least four times in the last month. exclusion criteria: * psychiatric comorbidity.

Keywords: behavioral treatment sleep paralysis narcolepsy type 1
intermittent fasting in nonalcoholic fatty liver disease

Conditions: Intermittent Fasting; Non-Alcoholic Fatty Liver Disease; Insulin Resistance; Obesity; Gut Microbiota

Summary: although preliminary evidence suggests that intermittent fasting mimic-diet (ifd) exerts stronger effects on body weight and metabolic parameters, which may link obesity, non-alcoholic fatty liver disease (nafld) and major chronic diseases, compared with continuous calorie restriction (ccr), there is a lack of well-powered intervention studies. this randomized controlled trial will test whether ifd, operationalized as the "5:2 diet," has stronger effects on anthropometric and body composition characteristics, and circulating metabolic biomarkers than ccr and a control regimen in adults with nafld.


Eligibility criteria:
inclusion criteria: * the diagnosed criteria of fatty liver by ultrasound were presence of two of the three following criteria: increased hepatic echogenicity compared with cortical of the right kidney, blurring of liver vasculature, and deep attenuation of the ultrasonographic signal. exclusion criteria: * excessive alcohol consumption (ethanol \> 140 g/wk for men and \> 70 g/wk for women), cirrhosis, viral hepatitis, cardiovascular disease, cancer, any consumption of nonsteroidal anti-inflammatory drugs, corticosteroids or prescriptive medicine that affect liver function, lipid and glucose metabolism.
psychological effects of h pylori associated gastritis

Conditions: H Pylori

Summary: the goals of this study 1. explore association between psychological factors and hpylori associated gastritis. 2. assess prevalence and severity of psychology symptoms among patients with h pylori associated gastritis and their effects on their life. 3. examine relation between demographic and clinical variables . 4. effect of eradication of h pylori on psychological status of patients.

one of the most prevalant chronic bacterial illness affecting people is it h.plyori infection. it affects at least 50% of people worldwide . it is a human gastrointestinal infection which is believed to be blammed for a number of gastric illness from chronic gastritis up to gastric cancer. numerous literature data suggest there is strong relation of anxiety disorders, stress or depression to somatic symptoms and this relation can undergo potentialization in case of appearance of pathogenic factors like helicobacter pylori infection , this relation can confirmed with many scientific reports , with the common use of antidepressants and anxiety relieving drugs in duodenal ulcer disease therapy. the close relationship of gastrointestinal function with brain function and the mental status is known as (gut brain axis). it has been reported that emotional factors induce changes in gastric physiology that physiological stress induces personality dependant gastric acid secretion changes and avariety of alterations in gastric motility. . the effect of numerous stress factors which injury mucosa of stomach and modify immunity of the patient so that the patient become more sensitive to be infected with h. pylori and infection become more aggressive and lead to manifestation of gastritis , duodenitis and gastric ulcer disease. mental stress is considered a major pathogenic factor for peptic ulcers and it is associated with increasing prevalence of gastric ulcersin patients is with or without h.pyloriinfection. another study revealed that depression is associated with food related symptoms as nausea and vomiting ,similarly it was showing that gastric information lead to an anxiety and depression like behaviors via neuroendocrine pathways in female not male. so the investigetors conducted this observational study to determine the most common physiological effect is of h.pylori associated gastritis in patients attending assiut university hospitals and how to deal with it to improve quality of life.

Eligibility criteria:
inclusion criteria: 1. all patients with h.pylori associated gastritis that diagnosed by endoscopy. 2. patients diagnosed by detection of h.pylori ag in stool exclusion criteria: 1. patients did not take antibiotics within last 2 weeks 2. patients did not take ppi within last 1 month 3. patients not with acute massive gitbleeding. 4. patients without eradication of h.pylor
vitamin c supplementation intervention

Conditions: Heart Failure

Summary: this study is to test a low-cost, simple vitamin c supplementation intervention, that is, comparing placebo to 500 mg/day vitamin c and 1 gram/day vitamin c daily to assess feasibility and acceptability of vitamin c supplementation and effects on serum vitamin c level, health-related quality of life (hrqol), symptom burden, oxidative stress, and cardiac function.

this study will address feasibility from the perspective of being able to: a) to detect significant differences in the serum vitamin c level after supplementation (3 months) between the intervention groups and the control group, b) to detect significant differences in health related quality of life (hrqol), symptom burden, oxidative stress, and cardiac function after vitamin c supplementation (3 months) between the intervention groups and the control group.

Eligibility criteria:
inclusion criteria: patents recruited will have a diagnosis of chronic hf, either preserved or reduced ejection fraction. the diagnosis and etiology of chronic hf will be confirmed by a hf cardiologist using established criteria. other criteria: * have undergone evaluation of hf and optimization of medical therapy, * vitamin c supplementation \<500 mg/day * have not been referred for heart transplantation, * able to read and speak english, * \>1 month from any inpatient hospitalization exclusion criteria: * history of renal stones or renal disease (serum creatinine \>1.5, * history of glucose-6-phosphate dehydrogenase deficiency (g6pd) and cognitive impairment that precludes giving informed consent or ability to follow protocol instructions * pregnant

Keywords: vitamin c supplementation